<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002490</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077404</org_study_id>
    <secondary_id>MRC-BS06</secondary_id>
    <secondary_id>EU-91019</secondary_id>
    <secondary_id>ISRCTN65282717</secondary_id>
    <nct_id>NCT00002490</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer</brief_title>
  <official_title>A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not known&#xD;
      whether receiving either radiation therapy, chemotherapy, or observation is more effective&#xD;
      for cancer of the bladder.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy,&#xD;
      chemotherapy, or observation following tumor surgery in treating patients who have bladder&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of adjuvant radical radiotherapy vs intravesical BCG or mitomycin&#xD;
           vs observation alone after endoscopic resection in terms of the progression rate and&#xD;
           survival of patients with stage I, grade 3 transitional cell carcinoma of the bladder.&#xD;
&#xD;
        -  Determine the toxicity of radical radiotherapy in these patients.&#xD;
&#xD;
        -  Determine the incidence of carcinoma in situ elsewhere in the bladder and its&#xD;
           correlation with the subsequent clinical outcome of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, extent of tumor (single tumor without carcinoma in situ (CIS) vs multiple tumors or&#xD;
      CIS), and WHO performance status. Patients with a single tumor and no CIS are randomized to&#xD;
      arm I or II. Patients with multiple tumors or CIS are randomized to arm II or III.&#xD;
&#xD;
        -  Arm I: Patients undergo observation only.&#xD;
&#xD;
        -  Arm II: Patients undergo radical radiotherapy 5 days a week for 6 weeks. Patients found&#xD;
           to be node positive on CT scan may undergo pelvic irradiation and remain on study.&#xD;
&#xD;
        -  Arm III: Patients receive intravesical BCG or mitomycin (at the discretion of the&#xD;
           physician) weekly for 6-12 weeks.&#xD;
&#xD;
      Patients on arms I and III are followed at 3 months after randomization. All patients are&#xD;
      followed at 6, 9, and 12 months and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1991</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of transitional cell carcinoma of the bladder&#xD;
&#xD;
               -  Stage T1 Nx M0, grade 3 disease&#xD;
&#xD;
               -  No muscle invasion at base of tumor&#xD;
&#xD;
               -  Diagnosis of this stage made within the past 6 months&#xD;
&#xD;
                    -  Earlier diagnosis of tumors with lower stage or grade allowed&#xD;
&#xD;
                    -  No history of higher stage urothelial tumors&#xD;
&#xD;
          -  Presence of partial involvement of bladder with carcinoma in situ (CIS) or&#xD;
             asymptomatic widespread CIS allowed&#xD;
&#xD;
               -  No widespread CIS causing severe symptoms&#xD;
&#xD;
          -  Prior complete transurethral resection of tumor with deep biopsy of underlying bladder&#xD;
             wall required&#xD;
&#xD;
          -  Disease currently amenable to adjuvant radiotherapy, followed by cystoscopy with&#xD;
             biopsies&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanomatous skin cancer or cervical&#xD;
             intraepithelial neoplasia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 1 prior adjuvant treatment with intravesical BCG&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior adjuvant treatment with intravesical chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Diathermic removal of associated small papillary growths allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J. Harland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Middlesex Hospital- Meyerstein Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Harland SJ: A randomised trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06). [Abstract] J Clin Oncol 23 (Suppl 16): A-4505, 379s, 2005.</citation>
  </results_reference>
  <verification_date>June 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage I bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

